# Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

> **NCT03644511** · — · TERMINATED · sponsor: **Bayer** · enrollment: 3 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT03644511
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-24
- **Primary completion:** 2019-07-18
- **Final completion:** 2019-09-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The interest of potential centers is very limited.
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644511, "Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03644511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*